ArticleOxford medical case reports2026
Type 3 Von Willebrand disease: two clinical cases of a rare disorder.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Von Willebrand disease (VWD) is the most common inherited coagulopathy, resulting from a deficiency of von Willebrand factor (VWF), which plays a central role in hemostasis. Type 3 VWD, the rarest and most severe form, is characterized by an almost complete absence of VWF, leading to severe and recurrent bleeding episodes. We report two pediatric cases of third-degree cousins, aged 3 and 2 years, born to consanguineous parents, who presented with severe hemorrhagic syndromes including profuse epistaxis, gingival bleeding, and anemia. Both had markedly prolonged activated partial thromboplastin time, reduced factor VIII, and severely diminished VWF activity and antigen levels, confirming the diagnosis of severe type 3 von Willebrand disease. Management included local hemostasis, avoidance of trauma, and prophylactic administration of plasma-derived VWF/FVIII before invasive procedures. These cases highlight the diagnostic and therapeutic challenges of managing severe inherited bleeding disorders in resource-limited settings, emphasizing the importance of early recognition, family education, and structured follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.